MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - May 22, 2012) -
Study Data Expected in Q4 2012
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based
Inc. today announced the successful completion of patient enrollment in
phase 1 clinical trial evaluating MOR208. MOR208 (formerly XmAb®5574)
potent anti-CD19 antibody with a proprietary modification to the Fc
that is being developedto treat B-cell malignancies. A total of 30 patients
relapsed or refractory chronic lymphocytic leukemia (CLL/SLL) have
randomized in the open-label, multi-dose, single-arm, dose-escalation study.
dose-limiting toxicity was observed and the trial protocol was amended
include a period of extended dosing for patients responding to treatment.
phase 1 trial was designed to assess the drug's safety,
pharmacokinetic profile and preliminary anti-tumor activity. Data from the
will become available in Q4 2012.
"We are excited about the excellent progress of the MOR208 program and
preparing the next steps of clinical development in additional B-
malignancies to quickly assess the broader commercial potential of
molecule," commented Dr. Arndt Schottelius, Chief Development Officer
MorphoSys AG. "The extended treatment period we were able to include in
phase 1 study could provide us with additional data on preliminary anti-
"MOR208 uses our XmAb ADCC technology to enhance its B-cell
properties," said Bassil Dahiyat, Ph.D., Chief Executive Officer of Xencor.
XmAb high ADCC technology has been applied to develop six antibodies that
now in clinical testing, demonstrating the technology's broad applicability."
In June 2010, MorphoSys AG and Xencor signed a worldwide exclusive license
collaboration agreement. The agreement provided MorphoSys with an
worldwide license to MOR208 for the treatment of cancer and other
Using Xencor's XmAb Fc enhancement technology, MOR208 has been engineered
possess significantly enhanced antibody-dependent cell-mediated
(ADCC), thus improving a key mechanism for tumor cell killing and
potential for enhanced efficacy compared to traditional antibodies for
treatment of cancer. MorphoSys will be solely responsible for further
development after successful completion of the phase 1 clinical trial.
plans to initiate additional clinical trials for MOR208 in non-
lymphoma (NHL) and acute lymphoblastic leukemia (ALL) in the fourth quarter
In total, MorphoSys currently has four proprietary clinical programs
including MOR208, MOR103, a fully human HuCAL antibody directed against GM-
(granulocyte macrophage-colony stimulating factor), in RA and MS, as well
MOR202, a HuCAL antibody targeting CD38, in multiple myeloma.
About Xencor, Inc.
Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein
Design Automation® technology platform, and is a leader in the field of
antibody engineering to significantly improve antibody half-life,
immune-regulatory function and potency. The company is advancing multiple
antibody drug candidates in the clinic, including XmAb®5871 targeting
and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb®2513
treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio of
biosuperior versions of blockbuster antibody drugs engineered for superior
half-life and dosing schedule. Xencor has entered into multiple partnerships
industry leaders such as Amgen, Pfizer, Centocor, MorphoSys, Boehringer
Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is
applying its suite of proprietary antibody Fc domains to improve antibody drug
candidates for traits such as sustained half-life and/or potency. More
information is available at www.xencor.com
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®,
RapMAT® and arYla® are registered trademarks of MorphoSys AG.
XmAb® is a registered trademark of Xencor, Inc.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE